Hypertension (Dallas, Tex. : 1979)
Hypertension (Dallas, Tex. : 1979)
Audio Summaries
Every issue of Hypertension (Dallas, Tex. : 1979) moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Specialties
Hypertension (Dallas, Tex. : 1979) covers research in these specialties.
Recent summaries
The latest articles summarized from Hypertension (Dallas, Tex. : 1979).
Subtypes of Hypertension 2 to 7 Years After First Pregnancy
Jun 9, 2026
The authors aimed to investigate the prevalence of different hypertensive subtypes (isolated diastolic, isolated systolic, and combined systolic-diastolic hypertension) in women 2 to 7 years after their first pregnancy, particularly in relation to prior hypertensive disorders of pregnancy. They found that isolated diastolic hypertension was the most common subtype, and women with a history of hypertensive disorders during pregnancy had a significantly higher risk of both combined systolic-diastolic and isolated diastolic hypertension. This highlights the potential for targeted cardiovascular risk reduction in postpartum women, especially those with a history of pregnancy-related hypertension.
Baroreceptor Mechanotransduction: Diverse Sensors, Unified Signals
Jun 9, 2026
The authors investigate the mechanisms of mechanotransduction in arterial baroreceptors, questioning whether specific ion channels like PIEZO1/2 are essential for barosensing or if other channels such as TRPs and ENaCs can also fulfill this role in a context-dependent manner. They aim to reconcile the diverse structural and functional characteristics of baroreceptors, suggesting that their ability to encode pressure stimuli is influenced by a complex interplay of channel composition, terminal architecture, and afferent excitability, rather than relying on a single mechanosensory pathway.
Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure
Jun 5, 2026
This study aimed to evaluate the effectiveness and safety of combining finerenone and empagliflozin in lowering systolic blood pressure (SBP) in patients with chronic kidney disease and type 2 diabetes, particularly examining the differences between combination therapy and monotherapy. The findings indicated that combination therapy significantly improved SBP reduction in participants with baseline SBP ≥130 mm Hg, while the reduction in urinary albumin-to-creatinine ratio was largely independent of early SBP changes. The authors suggest that further research with ambulatory blood pressure monitoring is needed to validate these results.